Risperdal Fends Off Generic Competition

Law360, New York (October 3, 2007, 12:00 AM EDT) -- A judge on Tuesday upheld Janssen Pharmaceutical NV's Risperdal patent in the face of a challenge by Apotex Inc., leaving Janssen with three fewer competitors in total vying for the antipsychotic.

In order to conserve resources, Apotex had already agreed to be bound by a final decision in Johnson & Johnson subsidiary Janssen's earlier parallel suits over the drug against fellow generics makers Mylan Pharmaceuticals Inc. and Dr. Reddy's Laboraties after all their appeals had been exhausted.

That promise didn't benefit Apotex in the long run....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.